HOM 5307 Exam 1 questions with
answers
2. The defining feature of a direct contract model is the HMO contracting directly with a
hospital to provide acute services to its members (T,F) - ANSWERS False
3. Hospitals purchased physician practices and employed physicians in the 1990s, but
will no longer do so (T,F) - ANSWERS False
6. The same methodology used to pay a hospital for inpatient care is usually also used
to pay for outpatient care (T,F) - ANSWERS False
7. The majority of prescriptions for behavioral health medications are written by non
psychiatrists (T, F) - ANSWERS True
8. One potential negative consequence of drug formularies with high copayments is:
A. Decreased use of the most cost-effective medications
B. Low copayments may be a barrier to adherence
C. Increased use of brand drugs
D. High copayments may be a barrier to adherence - ANSWERS D. High copayments
may be a barrier to adherence
11. Electronic clinical support systems are important in disease management (T, F) -
ANSWERS True
14. Electronic prescribing offers which of the following potential outcomes?
A. Improvement in physician drug formulary prescribing conformance
B. Reduction in drug interactions and resulting serious adverse effects
C. Reduction in prescribing and dispensing errors
D. All the above - ANSWERS D. All the above
16. What statement is true regarding the trends of traditional, non-specialty drugs
(mostly oral and topical drugs dispensed in community pharmacy) and specialty drugs
(biotech, injectables, high-cost orals)?
A. Most plans do not cover specialty drugs, except under the medical benefit,and
specialty products, therefore, are of no serious cost consequence to pharmacy benefits.
The number of generic drugs is declining due to lower manufacture costs and, as a
result, traditional (non-specialty) drug products remain the focus of most of the
pharmacy budget increases.
B. Traditional drug costs are rising rapidly due to continued launch of new, expensive
brand drugs, with only a few approved genericas. The specialty market cost trend is
declining as a result of biosimilar "generic" injectable products imported from Europe.
answers
2. The defining feature of a direct contract model is the HMO contracting directly with a
hospital to provide acute services to its members (T,F) - ANSWERS False
3. Hospitals purchased physician practices and employed physicians in the 1990s, but
will no longer do so (T,F) - ANSWERS False
6. The same methodology used to pay a hospital for inpatient care is usually also used
to pay for outpatient care (T,F) - ANSWERS False
7. The majority of prescriptions for behavioral health medications are written by non
psychiatrists (T, F) - ANSWERS True
8. One potential negative consequence of drug formularies with high copayments is:
A. Decreased use of the most cost-effective medications
B. Low copayments may be a barrier to adherence
C. Increased use of brand drugs
D. High copayments may be a barrier to adherence - ANSWERS D. High copayments
may be a barrier to adherence
11. Electronic clinical support systems are important in disease management (T, F) -
ANSWERS True
14. Electronic prescribing offers which of the following potential outcomes?
A. Improvement in physician drug formulary prescribing conformance
B. Reduction in drug interactions and resulting serious adverse effects
C. Reduction in prescribing and dispensing errors
D. All the above - ANSWERS D. All the above
16. What statement is true regarding the trends of traditional, non-specialty drugs
(mostly oral and topical drugs dispensed in community pharmacy) and specialty drugs
(biotech, injectables, high-cost orals)?
A. Most plans do not cover specialty drugs, except under the medical benefit,and
specialty products, therefore, are of no serious cost consequence to pharmacy benefits.
The number of generic drugs is declining due to lower manufacture costs and, as a
result, traditional (non-specialty) drug products remain the focus of most of the
pharmacy budget increases.
B. Traditional drug costs are rising rapidly due to continued launch of new, expensive
brand drugs, with only a few approved genericas. The specialty market cost trend is
declining as a result of biosimilar "generic" injectable products imported from Europe.
